Actinium to present Phase 1 ATNM-400 study at EANM 2026
The company announced an oral presentation highlighting its first-in-human Phase 1 study of ATNM-400, a non-PSMA-targeting radiotherapy in prostate cancer.
The company announced an oral presentation highlighting its first-in-human Phase 1 study of ATNM-400, a non-PSMA-targeting radiotherapy in prostate cancer.